초록 ▼

A packaged composition of 1-(2-methylpropyl)-1H-imidazo4,5-cquinolin-4-amine dissolved in a fatty acid formulation and contained in a laminated packaging material having a contact layer that includes an acrylonitrile-methyl acrylate copolymer; an outer layer; and a moisture barrier layer disposed be

A packaged composition of 1-(2-methylpropyl)-1H-imidazo4,5-cquinolin-4-amine dissolved in a fatty acid formulation and contained in a laminated packaging material having a contact layer that includes an acrylonitrile-methyl acrylate copolymer; an outer layer; and a moisture barrier layer disposed between the contact layer and outer layer.

대표청구항 ▼

1. A packaged composition containing an imiquimod formulation and a durable laminated packaging material for storing the imiquimod formulation therein, the packaged composition enabling storage of the imiquimod formulation for an extended period of time within the durable laminated packaging materia

1. A packaged composition containing an imiquimod formulation and a durable laminated packaging material for storing the imiquimod formulation therein, the packaged composition enabling storage of the imiquimod formulation for an extended period of time within the durable laminated packaging material, said packaged composition comprising: (a) the durable laminated packaging material forming a pouch comprising:(i) a contact layer comprising an acrylonitrile-methyl acrylate copolymer;(ii) an outer layer;(iii) a moisture barrier layer disposed between the contact layer and the outer layer; and(b) the imiquimod formulation comprising 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine and a fatty acid;wherein, the imiquimod formulation is enclosed within the durable laminated packaging material and is in direct contact with the contact layer; andwherein the imiquimod formulation, when enclosed within the pouch and in direct contact with the contact layer, is stable for at least about 6 weeks at about 60° C. and at ambient relative humidity (RH), andwherein the durable laminated packaging material, when stored in direct contact with the imiquimod formulation at about 40° C. and at about 76% RH, remains durable over a period of at least about 1 month. 2. The packaged composition of claim 1, wherein the imiquimod formulation enclosed within the durable laminated packaging material is stable for at least about 6 months at about 40° C., and at about 75% RH. 3. The packaged composition of claim 1, wherein the imiquimod formulation maintained within the durable laminated packaging material is stable for at least about 1 year at about 30° C. and at about 65% RH. 4. The packaged composition of claim 1, wherein the, the imiquimod formulation maintained within the durable laminated packaging material is stable for at least about 2 years at about 25° C. and at about 60% RH. 5. The packaged composition of claim 1, wherein the durable laminated packaging material, when stored in contact with the imiquimod formulation at about 40° C. and at about 75% RH, remains durable over a period of at least about 3 months. 6. The packaged composition of claim 1, wherein the durable laminated packaging material, when stored in contact with the imiquimod formulation at about 25° C. and at about 80% RH, remains durable over a period of at least about 3 months. 7. The packaged composition of claim 1, wherein the durable laminated packaging material, when stored in contact with the imiquimod formulation at about 40° C. and at about 75% RH, remains durable over a period of at least about 6 months. 8. The packaged composition of claim 1, wherein the durable laminated packaging material, when stored in contact with the imiquimod formulation at about 25° C. and at about 60% RH, remains durable over a period of at least about 6 months. 9. The packaged composition of claim 1, wherein the outer layer includes a 12-micron thick polyethelene terephthlate layer, the moisture barrier layer includes a 9-micron thick aluminum layer, and further comprises an adhesive tie layer, the adhesive tie layer including white low density polyethylene, and being disposed between the moisture barrier layer and the outer layer. 10. The packaged composition of claim 9 further comprising an adhesive disposed between the contact layer and the moisture barrier layer. 11. The packaged composition of claim 1, wherein the contact layer is 25 microns to 80 microns thick. 12. The packaged composition of claim 1, wherein the moisture barrier layer is 5 microns to 15 microns thick. 13. The packaged composition of claim 1, wherein the outer layer is 5 millimeters to 20 millimeters thick. 14. The packaged composition of claim 1, wherein the moisture barrier layer comprises a metal foil. 15. The packaged composition of claim 1, wherein the outer layer comprises an organic polymer. 16. The packaged composition of claim 1, wherein the outer layer comprises polyethylene terephthalate. 17. The packaged composition of claim 1, wherein the fatty acid is selected from the group consisting of isostearic acid, oleic acid, myristic acid, palmitic acid, palmitoleic acid, margaric acid, stearic acid, linoleic acid, linolenic acid, and mixtures thereof. 18. The packaged composition of claim 17, wherein the fatty acid is an isostearic acid, an oleic acid or mixtures thereof. 19. The packaged composition of claim 1, wherein the fatty acid is present in an amount of at least about 15% by weight based on the total weight of the imiquimod formulation. 20. The packaged composition of claim 1, wherein the fatty acid is present in an amount of at least about 20% by weight based on the total weight of the imiquimod formulation. 21. The packaged composition of claim 1, wherein the fatty acid is present in an amount of about 25% by weight based on the total weight of the imiquimod formulation. 22. The packaged composition of claim 1, wherein 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation. 23. The packaged composition of claim 22, wherein the fatty acid is an isostearic acid. 24. The packaged composition of claim 22, wherein the fatty acid is an oleic acid. 25. The packaged composition of claim 22, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 26. The packaged composition of claim 1, wherein the imiquimod formulation further comprises a preservative, the preservative being selected from the group consisting of methylparaben, propylparaben, benzyl alcohol and mixtures thereof. 27. The packaged composition of claim 1, wherein the imiquimod formulation further comprises an emollient, an emulsifier, a thickener, a solubilizing agent, or mixtures thereof. 28. The packaged composition of claim 9, wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation and the fatty acid is an isostearic acid. 29. The packaged composition of claim 9, wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation and the fatty acid is an oleic acid. 30. The packaged composition of claim 9, wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation and the fatty acid is a mixture of an isostearic acid and an oleic acid. 31. The packaged composition of claim 1, wherein the durable laminated packaging material is formed into a sachet with a bottle-shaped area containing about 250 mg of the imiquimod formulation, and wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation. 32. The packaged composition of claim 31, wherein the fatty acid is an isostearic acid. 33. The packaged composition of claim 31, wherein the fatty acid is an oleic acid. 34. The packaged composition of claim 31, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 35. The packaged composition of claim 9, wherein the durable laminated packaging material is formed into a sachet with a bottle-shaped area containing about 250 mg of the imiquimod formulation, and wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation. 36. The packaged composition of claim 17, wherein the durable laminated packaging material is formed into a sachet with a bottle-shaped area containing about 250 mg of the imiquimod formulation, and wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation. 37. The packaged composition of claim 19, wherein the durable laminated packaging material is formed into a sachet with a bottle-shaped area containing about 250 mg of the imiquimod formulation, and wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation. 38. The packaged composition of claim 20, wherein the durable laminated packaging material is formed into a sachet with a bottle-shaped area containing about 250 mg of the imiquimod formulation, and wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation. 39. The packaged composition of claim 21, wherein the durable laminated packaging material is formed into a sachet with a bottle-shaped area containing about 250 mg of the imiquimod formulation, and wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation. 40. The packaged composition of claim 27, wherein the durable laminated packaging material is formed into a sachet with a bottle-shaped area containing about 250 mg of the imiquimod formulation, and wherein the 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 5% by weight of the imiquimod formulation. 41. The packaged composition of claim 35, wherein the fatty acid is an isostearic acid. 42. The packaged composition of claim 35, wherein the fatty acid is an oleic acid. 43. The packaged composition of claim 35, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 44. The packaged composition of claim 36, wherein the fatty acid is an Isostearic acid. 45. The packaged composition of claim 36, wherein the fatty add is an oleic acid. 46. The packaged composition of claim 36, wherein the fatty acid is a mixture of isostearic acid and oleic add. 47. The packaged composition of claim 37, wherein the fatty add is an isostearic acid. 48. The packaged composition of claim 37, wherein the fatty acid is an oleic add. 49. The packaged composition of claim 37, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 50. The packaged composition of claim 38, wherein the fatty acid is an isostearic acid. 51. The packaged composition of claim 38, wherein the fatty acid is an oleic acid. 52. The packaged composition of claim 38, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 53. The packaged composition of claim 39, wherein the fatty acid is an isostearic acid. 54. The packaged composition of claim 39, wherein the fatty acid is an oleic acid. 55. The packaged composition of claim 39, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 56. The packaged composition of claim 40, wherein the fatty acid is isostearic acid. 57. The packaged composition of claim 40, wherein the fatty acid is an oleic acid. 58. The packaged composition of claim 40, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 59. The packaged composition of claim 1, wherein the imiquimod formulation further comprises: at least one of: (a) a preservative;(b) an emollient;(c) an emulsifier;(d) a thickener;(e) a solubilizer;(f) a humectant; and(g) water. 60. The packaged composition of claim 59, wherein the fatty acid is an isostearic acid. 61. The packaged composition of claim 59, wherein the fatty acid is an oleic acid. 62. The packaged composition of claim 59, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 63. The packaged composition of claim 59, wherein the preservative is selected from the group consisting of methylparaben, benzyl alcohol and propylparaben, the emollient is selected from the group consisting of cetyl alcohol, stearyl alcohol and petrolatum, the emulsifier is selected from the group consisting of polysorbate 60 and sorbitan monostearate, the thickener is selected from the group consisting of a gum, cetyl alcohol and stearyl alcohol, and the humectant is glycerin. 64. The packaged composition of claim 60, wherein the preservative is selected from the group consisting of methylparaben, benzyl alcohol and propylparaben, the emollient is selected from the group consisting of cetyl alcohol, stearyl alcohol and petrolatum, the emulsifier is selected from the group consisting of polysorbate 60 and sorbitan monostearate, the thickener is selected from the group consisting of a gum, cetyl alcohol and stearyl alcohol, and the humectant is glycerin. 65. The packaged composition of claim 61, wherein the preservative is selected from the group consisting of methylparaben, benzyl alcohol and propylparaben, the emollient is selected from the group consisting of cetyl alcohol, stearyl alcohol and petrolatum, the emulsifier is selected from the group consisting of polysorbate 60 and sorbitan monostearate, the thickener is selected from the group consisting of a gum, cetyl alcohol and stearyl alcohol, and the humectant is glycerin. 66. The packaged composition of claim 62, wherein the preservative is selected from the group consisting of methylparaben, benzyl alcohol and propylparaben, the emollient is selected from the group consisting of cetyl alcohol, stearyl alcohol and petrolatum, the emulsifier is selected from the group consisting of polysorbate 60 and sorbitan monostearate, the thickener is selected from the group consisting of a gum, cetyl alcohol and stearyl alcohol, and the humectant is glycerin. 67. The packaged composition of claim 1, wherein said imiquimod formulation is a cream. 68. The packaged composition of claim 1, wherein said imiquimod formulation is an ointment. 69. The packaged composition of claim 1, wherein said imiquimod formulation is a lotion. 70. The packaged composition of claim 1, wherein 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of no more than about 9% by weight of the imiquimod formulation. 71. The packaged composition of claim 70, wherein the fatty acid is an isostearic acid. 72. The packaged composition of claim 70, wherein the fatty acid is an oleic acid. 73. The packaged composition of claim 70, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 74. The packaged composition of claim 70, wherein said imiquimod formulation is a cream. 75. The packaged composition of claim 70, wherein said imiquimod formulation is an ointment. 76. The packaged composition of claim 1, wherein 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of no more than about 5% by weight of the imiquimod formulation. 77. The packaged composition of claim 76, wherein the fatty acid is an isostearic acid. 78. The packaged composition of claim 76, wherein the fatty acid is an oleic acid. 79. The packaged composition of claim 76, wherein the fatty acid is a mixture of isostearic acid and oleic acid. 80. The packaged composition of claim 76, wherein said imiquimod formulation is a cream. 81. The packaged composition of claim 76, wherein said imiquimod formulation is an ointment.